Hyderabad-based biotech startup Utopia Therapeutics has raised $1.5 million in seed funding from Whale Tank.
Utopia Therapeutics focuses on developing next-generation vaccines for chronic metabolic diseases like obesity.
The startup plans to use the funding to advance the preclinical development of its lead candidate, UT009, targeting obesity.
UT009 is an immunotherapeutic vaccine designed to reduce fat accumulation and improve metabolic health.
The investment will support UT009's progress towards regulatory toxicology studies, IND-enabling milestones, and Phase I clinical trials.
Utopia Therapeutics founders, Dr. Uday Saxena and Dr. Gopi Kadiyala, aim to redefine obesity treatment with UT009.
The startup's innovative approach differentiates UT009 from current obesity drugs by addressing the root causes of weight gain.
Dr. Jitendra Kumar, MD of BIRAC, praised the scientific and entrepreneurial growth demonstrated by companies like Utopia Therapeutics in India.
Whale Tank's Managing Partner, Dr. Markandeya Gorantla, emphasized Utopia's potential to disrupt the obesity market with its scientifically rigorous approach.
Utopia Therapeutics' funding history includes support from BIRAC, reflecting the encouraging ecosystem for deep-tech science in India.
The startup aims to bring Immunotherapeutics to the forefront of chronic disease management.
The investment will facilitate Utopia's journey towards clinical translation and potential global impact in addressing metabolic disorders.
Whale Tank's investment in Utopia signifies confidence in the startup's bold and innovative mission.
Utopia Therapeutics' founders are thrilled to have Whale Tank as a strategic partner in their quest to reinvent obesity treatment.
The seed funding enables Utopia Therapeutics to accelerate the development of UT009 and progress towards clinical trials.
The startup's work represents a significant step towards addressing the global obesity epidemic with new scientific approaches.